An on-demand therapy that works on desire in the brain, not blood flow in the body.
PT-141 (bremelanotide) is a melanocortin receptor agonist that acts centrally in the brain rather than on vascular blood flow, which is what distinguishes it from PDE5 inhibitors like sildenafil. Its active ingredient is FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women, and it is prescribed off-label for other patients under physician evaluation.
Dosed as needed ahead of anticipated activity rather than on a fixed daily or weekly schedule.
Works through melanocortin receptors in the brain that influence sexual desire and arousal pathways, independent of vascular blood flow.
Because it does not rely on the nitric oxide/vascular pathway, it is sometimes considered for patients who have not responded well to PDE5 inhibitors.
Bremelanotide is the same active ingredient approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women, with an established safety and side-effect profile from that approval.
Its central mechanism is studied specifically around subjective desire and arousal, distinct from medications that primarily support physical response.
Built-in monthly dose caps and blood pressure monitoring keep use within a bounded, medically supervised protocol rather than open-ended self-dosing.
PT-141 is a synthetic analog derived from the melanocortin peptide family. Unlike PDE5 inhibitors, which enhance blood flow through the nitric oxide pathway, bremelanotide acts on melanocortin receptors in the central nervous system associated with sexual arousal circuitry.
Bremelanotide binds melanocortin-4 receptors concentrated in the hypothalamus, a region involved in regulating sexual arousal and desire.
Downstream activity involving dopaminergic pathways is thought to increase subjective desire and arousal responsiveness.
Because the mechanism does not depend on nitric oxide-mediated blood flow, it works through a different route than PDE5 inhibitors.
Effects begin within about 45 minutes and are intended for a single anticipated encounter rather than continuous coverage.
Sildenafil-class medications work on vascular smooth muscle to improve blood flow; they do not directly address desire. Bremelanotide's central mechanism is why it is studied and used for low desire specifically, and why the two approaches are sometimes combined rather than treated as interchangeable.
Bremelanotide's on-label approval (as Vyleesi) is specific to premenopausal women with hypoactive sexual desire disorder, dosed via a fixed autoinjector. Off-label use in men or postmenopausal women, and compounded dosing formats, have a thinner trial base than the on-label indication — your physician will be clear about which use applies to you.
Bremelanotide causes a transient rise in blood pressure and a modest drop in heart rate after dosing. This is expected and typically resolves within hours, but it is why uncontrolled hypertension and known cardiovascular disease are contraindications, and why we monitor blood pressure at intake and follow-up.
Frequent, repeated melanocortin receptor activation has been associated with focal skin hyperpigmentation (notably on the face, gums, and breast tissue) in a minority of patients, which is usually reversible after stopping. Staying within labeled frequency limits is part of managing that risk.
The RECONNECT phase 3 trials found bremelanotide significantly improved sexual desire and reduced distress in premenopausal women with HSDD, with nausea and flushing as the most common side effects.
Obstetrics & Gynecology
Phase 2b dose-finding study establishing the 1.75 mg subcutaneous dose used in later approval trials, based on efficacy and tolerability.
Journal of Sexual Medicine
Early placebo-controlled evaluation of PT-141 in men with erectile dysfunction, showing central pro-erectile activity distinct from PDE5 inhibitors.
International Journal of Impotence Research
Illustrative only. Your physician sets and adjusts your schedule based on tolerance, labs and rate of progress — escalation is never automatic.
| Phase | Dose | Clinical note |
|---|---|---|
| First dose | 1.75 mg subcutaneous | Taken at least 45 minutes before anticipated activity; assess response and side effects. |
| Ongoing use | As needed, per response | No more than one dose in 24 hours. |
| Monthly limit | Up to 8 doses per month | Cap set to manage hyperpigmentation and blood pressure risk. |
| Follow-up | — | Physician reviews blood pressure and response before continuing. |
Most side effects are dose-dependent and resolve with slower titration. Your care team is reachable by message, and holding a dose is always an option.
| Therapy | Mechanism | Avg. weight change | Frequency |
|---|---|---|---|
| PT-141 (Bremelanotide) | Central melanocortin agonist | — | As needed |
| Sildenafil / Tadalafil (PDE5 inhibitor) | Vascular, nitric oxide pathway | — | As needed |
| Testosterone Therapy | Hormonal replacement | — | Daily/weekly, ongoing |
The active ingredient, bremelanotide, is the same. Vyleesi is the FDA-approved autoinjector for premenopausal women with HSDD. What we prescribe may be compounded and used for a broader group of patients under physician evaluation, which your physician will explain clearly.
Take it at least 45 minutes before anticipated activity. Effects generally build over a few hours and taper afterward; it is not intended as a continuous daily therapy.
Yes, off-label, and it has been studied in men going back to its earliest development. Your physician will review whether it is appropriate given your history and other treatments tried.
A temporary rise in blood pressure and drop in heart rate after dosing is expected and usually resolves within hours. This is why blood pressure history is reviewed carefully before prescribing.
No more than once in 24 hours, and generally capped around eight doses per month, to manage blood pressure effects and the small risk of skin hyperpigmentation with frequent use.
The clinical gold standard for appetite regulation.
View protocolDual incretin action for the deepest documented weight reduction.
View protocolA gastric peptide studied for systemic tissue repair.
View protocolA synthetic fragment of Thymosin Beta-4 studied for soft-tissue recovery.
View protocolA paired secretagogue protocol that supports your own growth hormone rhythm.
View protocolA mitochondrial cofactor protocol for energy, focus and cellular repair.
View protocolThe same GLP-1 signal, taken as a daily oral dose instead of a weekly injection.
View protocolA mitochondrial-derived peptide studied for metabolic flexibility and exercise-like signaling.
View protocolIntranasal peptides studied for focus, stress resilience and neurotrophic support.
View protocolThe original growth hormone-releasing peptide — simpler and gentler than newer secretagogue combinations.
View protocolA two-minute intake, reviewed by a licensed physician. No obligation, no membership fee.